Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...

Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...

The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.

Pfizer will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs, resulting in the submission of false claims to federal ...

Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs ...

Pfizer (PFE), on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical (BHVN), has agreed to pay $59,746,277 to resolve allegations ...